Twist Bioscience Corp vs Yum! Brands, Inc. — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Yum! Brands, Inc. trades at $144.94 (market cap $40.80B). The key difference: Yum! Brands, Inc. is far larger — about 4.8× Twist Bioscience Corp's market cap, and Yum! Brands, Inc. pays a 2.01% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | YUM | |
|---|---|---|
Market Cap | $8.42B | $40.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $153.10 | $168.16 |
52-Week Low | $24.16 | $138.21 |
Enterprise Value | $8.35B | $52.40B |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
YUM trades at $149.59, down 0.74% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $8.21B and net income of $1.56B in 2025, with a P/E ratio of 18.83. Recent developments include the sale of Pizza Hut for approximately $1.5B to LongRange Capital, with proceeds aimed at debt reduction and share buybacks, alongside a declared $0.75 quarterly dividend.
The outlook is mixed: analyst consensus is a buy with a $173.60 price target, but high debt and a legal investigation pose risks. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. The stock offers potential upside from strategic refocusing and buybacks, balanced against consumer spending pressures and leverage concerns.
Trailing returns across standard periods
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →